YOU HAVE 960 PIXELS WIDTH TO PLAY WITH FOR WHATEVER YOU WANT TO EMBED! Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas metus nulla, commodo a sodales sed, dignissim pretium nunc. Nam et lacus neque. Sed volutpat ante id mauris laoreet vestibulum. Nam blandit felis non neque cursus aliquet. Morbi vel enim dignissim massa dignissim commodo vitae quis tellus. Nunc non mollis nulla. Sed consectetur elit id mi consectetur bibendum. Ut enim massa, sodales tempor convallis et, iaculis ac massa. Etiam suscipit nisl eget lorem pellentesque quis iaculis mi mattis. Aliquam sit amet purus lectus. Maecenas tempor ornare sollicitudin.
Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.
Proin nec turpis eget dolor dictum llsdklsacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.
Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.
Ever since the discovery of restriction enzymes in 1978, a new era of synthetic biology was ushered in, an era in which scientific discovery would meet engineering, and promised the ability to eventually control and modulate gene expression. Illinois Synth has a deep confidence not only in the growth of synthetic biology as an industry, but in the growing demand for technologies that will allow the modulation of gene expression in RNA. Such tools currently take the form of RNA recognition motifs, K Homology proteins, and CCCH Zinc Finger proteins that in many cases do not exhibit sequence specific binding, or are unable to be programmed to recognize specific, desired ssRNA sequences. With regard to the use of an in vivo enzymatic cascade to produce piceatannol, our analysis has shown that such a method would be faster, more efficient, and lower cost than chemical synthesis of the compound, which is the only current mode or production.
Our competitive analysis was broken into two components: • Analysis of alternative RNA-binding proteins • Analysis of alternative ways to produce piceatannol
Analysis of alternative ways to bind to RNA yielded protein domains that are not as site specific as the PUF domain (8 nucleotide sequence specificity), and/or are uncustomizable whereas PUF can be programmed to recognize a desired ssRNA sequence while being tethered to a functional domain such as an endonuclease. Chemical synthesis is the only current mode of production of piceatannol, and has proven to be expensive due to the inefficiency of the (insert) chemical process. Tocris Bioscience, in particular, has a base rate of $19/mg of piceatannol. Additionally, instead of competing directly with large pharmaceutical companies to produce piceatannol at a low cost, we intend to license our technology to companies interested in using our RNA scaffold.
The two product lines being developed by Illinois Synth are as follows: • Gene Expression Modulator (GEM) Toolkit • In Vivo Optimized Piceatannol Cascade (IOPiC)
Our GEM Toolkit will provide an extremely novel, and efficient way to regulate and modulate gene expression in ssRNA. We expect such a toolkit to provide a high degree of utility to researchers interested in varying gene expression levels. Additionally, we believe IOPiC will provide a low cost, biological alternative to achieve the production of piceatannol without involving expensive chemical processes.
Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.
"
